NO20084906L - DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer - Google Patents

DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer

Info

Publication number
NO20084906L
NO20084906L NO20084906A NO20084906A NO20084906L NO 20084906 L NO20084906 L NO 20084906L NO 20084906 A NO20084906 A NO 20084906A NO 20084906 A NO20084906 A NO 20084906A NO 20084906 L NO20084906 L NO 20084906L
Authority
NO
Norway
Prior art keywords
trell
preparation
dna
necrosis factor
tumor necrosis
Prior art date
Application number
NO20084906A
Other languages
English (en)
Inventor
Yves Chicheportiche
Jeffrey L Browning
Original Assignee
Faculty Of Medicine Of The Uni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20084906L publication Critical patent/NO20084906L/no
Application filed by Faculty Of Medicine Of The Uni filed Critical Faculty Of Medicine Of The Uni

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Foreliggende oppfinnelse vedrører en tumornekrosefaktorrelatert ligand (TRELL), et nytt medlem av tumornekrosefaktorfamilien, (TNF), modifisert TRELL og farmasøytiske sammensetninger omfattende disse. 1
NO20084906A 1996-08-07 2008-11-21 DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer NO20084906L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2354196P 1996-08-07 1996-08-07
US2851596P 1996-10-18 1996-10-18
US4082097P 1997-03-18 1997-03-18
PCT/US1997/013945 WO1998005783A1 (en) 1996-08-07 1997-08-07 A tumor necrosis factor related ligand

Publications (1)

Publication Number Publication Date
NO20084906L true NO20084906L (no) 1999-04-06

Family

ID=27362110

Family Applications (2)

Application Number Title Priority Date Filing Date
NO990550A NO326967B1 (no) 1996-08-07 1999-02-05 Tumornekrosefaktor-relatert ligand (TRELL), rekombinant DNA som koder for TRELL, farmasøytiske sammensetninger inneholdende slike, samt antistoff spesifikt reaktivt med TRELL
NO20084906A NO20084906L (no) 1996-08-07 2008-11-21 DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO990550A NO326967B1 (no) 1996-08-07 1999-02-05 Tumornekrosefaktor-relatert ligand (TRELL), rekombinant DNA som koder for TRELL, farmasøytiske sammensetninger inneholdende slike, samt antistoff spesifikt reaktivt med TRELL

Country Status (25)

Country Link
EP (2) EP0956351B1 (no)
JP (3) JP4161084B2 (no)
KR (1) KR100543730B1 (no)
CN (2) CN1308451C (no)
AT (1) ATE307204T1 (no)
AU (1) AU736289B2 (no)
BG (1) BG64779B1 (no)
BR (1) BR9711046A (no)
CA (1) CA2262756C (no)
CZ (1) CZ297387B6 (no)
DE (1) DE69734397T2 (no)
DK (1) DK0956351T3 (no)
EA (1) EA003187B1 (no)
EE (1) EE05276B1 (no)
ES (1) ES2251737T3 (no)
HU (1) HU226787B1 (no)
IL (1) IL128407A (no)
IS (1) IS2606B (no)
NO (2) NO326967B1 (no)
NZ (1) NZ334107A (no)
PL (1) PL188102B1 (no)
SI (1) SI0956351T1 (no)
SK (1) SK288012B6 (no)
TR (1) TR199900903T2 (no)
WO (1) WO1998005783A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EP1967587A1 (en) * 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
DE19829550C1 (de) * 1998-07-02 2000-01-27 Bosch Gmbh Robert Vorrichtung zum Verbinden von Bauteilen
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
WO2001035995A2 (en) * 1999-11-19 2001-05-25 Tittle Thomas V Tr3-specific binding agents and methods for their use
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
EP1239869B1 (en) * 1999-12-20 2013-08-28 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
EP1558640B1 (en) * 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
NZ564092A (en) 2005-05-27 2010-05-28 Biogen Idec Inc TWEAK binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
KR101584416B1 (ko) 2010-10-05 2016-01-13 에프. 호프만-라 로슈 아게 인간 tweak에 대한 항체 및 그의 용도
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
CN110023499A (zh) * 2016-10-24 2019-07-16 拜欧亿思有限公司 肿瘤坏死因子-α(TNF-α)结合适配体及其治疗用途
CN112567037B (zh) * 2018-04-20 2025-07-04 周美吟 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途
JP2024516548A (ja) 2021-04-08 2024-04-16 ジョスリン ダイアビーティス センター インコーポレイテッド 腎機能低下の診断及び予測の方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
IE902820A1 (en) 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
EP0531080A3 (en) 1991-09-04 1993-12-29 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein

Also Published As

Publication number Publication date
NZ334107A (en) 2000-06-23
NO990550D0 (no) 1999-02-05
IL128407A0 (en) 2000-01-31
NO326967B1 (no) 2009-03-23
DE69734397T2 (de) 2006-07-06
EP1591530A3 (en) 2009-04-08
EE05276B1 (et) 2010-02-15
WO1998005783A1 (en) 1998-02-12
EA199900187A1 (ru) 1999-08-26
EA003187B1 (ru) 2003-02-27
NO990550L (no) 1999-04-06
CZ297387B6 (cs) 2006-11-15
KR100543730B1 (ko) 2006-01-23
CN1232503A (zh) 1999-10-20
JP2001505407A (ja) 2001-04-24
HU226787B1 (en) 2009-10-28
HK1025994A1 (en) 2000-12-01
BG103169A (en) 2000-06-30
DE69734397D1 (de) 2006-03-02
SK15799A3 (en) 2000-03-13
ATE307204T1 (de) 2005-11-15
CN101024831A (zh) 2007-08-29
EP0956351A1 (en) 1999-11-17
KR20000029877A (ko) 2000-05-25
JP2007204480A (ja) 2007-08-16
DK0956351T3 (da) 2006-02-20
AU3829497A (en) 1998-02-25
EP1591530B1 (en) 2015-02-25
AU736289B2 (en) 2001-07-26
IS2606B (is) 2010-04-15
CN1308451C (zh) 2007-04-04
EE9900043A (et) 1999-08-16
JP2009183294A (ja) 2009-08-20
PL188102B1 (pl) 2004-12-31
CZ40399A3 (cs) 1999-08-11
JP4411330B2 (ja) 2010-02-10
BR9711046A (pt) 2000-01-11
EP1591530A2 (en) 2005-11-02
CA2262756A1 (en) 1998-02-12
PL331583A1 (en) 1999-07-19
IL128407A (en) 2007-07-24
EP0956351B1 (en) 2005-10-19
TR199900903T2 (xx) 1999-06-21
HUP9903921A3 (en) 2000-08-28
BG64779B1 (bg) 2006-03-31
SK288012B6 (sk) 2012-10-02
SI0956351T1 (sl) 2006-02-28
CA2262756C (en) 2012-06-12
ES2251737T3 (es) 2006-05-01
EP1591530B8 (en) 2015-04-22
IS4967A (is) 1999-02-05
HUP9903921A2 (hu) 2000-03-28
JP4161084B2 (ja) 2008-10-08

Similar Documents

Publication Publication Date Title
EA200000311A1 (ru) Новый белок иммунной системы - кау
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
TR199900903T2 (xx) Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
TW261615B (no)
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
EP1005539A4 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
FI972170A0 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
FI850814A7 (fi) Proteiineja, farmaseuttisia seoksia, geenejä, vektoreita, isäntäorgan ismeja ja menetelmiä niiden tuottamiseksi.
SG128403A1 (en) Tnf-receptors, tnf binding proteins and dnas coding for them
AU666482B2 (en) Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
EP1019500A4 (en) NEW IFN RECEPTOR 1 BINDING PROTEINS, ENCODING DNA AND METHOD FOR REGULATING THE CELLULAR RESPONSE TO INTERFERON
ATE288959T1 (de) Men1, mit typ 1 multipler endokriner neoplasie assoziiertes gen, meninpolypeptide und deren verwendungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application